Fig. 2From: Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case seriesRepresentative CT images from a 79-year-old man with advanced Merkel cell carcinoma. He experienced progressive disease after receiving pembrolizumab (two left panels). He then received ipilimumab + nivolumab + radiotherapy to cervical adenopathy, to which he developed a partial response (RECIST v1.1) 17 weeks into combinatorial therapy (right panel). PR was ongoing at 8 months when the patient died from complications related to encephalopathy, likely immune-mediated (i.e., a toxicity related to immune checkpoint inhibitor therapy)Back to article page